Genome Pharmaceuticals (Pvt.) Ltd.
Manufacturer & importer Has products under both a manufacturing licence (DML) and a sale licence (DSL). Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Rawalpindi · Pakistan
Pakistan pharmaceutical manufacturer with a Hattar production facility and activities spanning manufacturing, marketing, import and export of specialized medicines.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- Plaza #63, Wallayat Complex, Opposite Anarkali, Bahria Town Phase 7, Rawalpindi, Pakistan
- Website
- genomepharmaceuticals.com ↗
- Phone
- +92 51 5172521
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Genome Pharmaceuticals (Pvt.) Ltd. is priced against the market
145 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Qupin SR-50 | Quetiapine | 50 mg | Sustained-release tablet | 10 x 10's | 074544 | PKR 4,667.70 | PKR 46.68/tablet | No comparator |
| Qupin-100 | Quetiapine | 100 mg | Tablet | 3 x 10's | 053564 | PKR 2,537.05 | PKR 84.57/tablet | 🔒 Pharma Pro |
| Qupin-25 | Quetiapine | 25 mg | Tablet | 3 x 10's | 053563 | PKR 704.74 | PKR 23.49/tablet | 🔒 Pharma Pro |
| Repitant | Aprepitant | 40 mg | Capsule | 2's | 088013 | PKR 1,998.03 | PKR 999.02/capsule | 🔒 Pharma Pro |
| Repitant | Aprepitant | 80 mg | Capsule | 2's | 088014 | PKR 3,336.92 | PKR 1,668.46/capsule | 🔒 Pharma Pro |
| Repitant | Aprepitant | 125 mg | Capsule | 1's | 088015 | PKR 2,360.34 | PKR 2,360.34/capsule | 🔒 Pharma Pro |
| Repitant | Aprepitant | 80 mg | Capsule | 80mg 2's & 125mg 1's | 101414 | PKR 5,327.40 | — | No comparator |
| Repol | Loperamide HCl | 2 mg | Capsule | 6 x 10's | 074558 | PKR 199.19 | PKR 3.32/capsule | 🔒 Pharma Pro |
| Riperidon-1 | Risperidone | 1 mg | Tablet | 1 x 10's | 053560 | PKR 239.34 | PKR 23.93/tablet | 🔒 Pharma Pro |
| Riperidon-2 | Risperidone | 2 mg | Tablet | 1 x 10's | 053561 | PKR 388.93 | PKR 38.89/tablet | 🔒 Pharma Pro |
| Riperidon-3 | Risperidone | 3 mg | Tablet | 1 x 10's | 053562 | PKR 598.35 | PKR 59.84/tablet | 🔒 Pharma Pro |
| Sevoflurane | Sevoflurane | 100% | Inhalation liquid | 1's(250ml) | 115721 | PKR 12,570.19 | — | No comparator |
| Sliczole-2.5 | Letrozole | 2.5 mg | Tablet | 1 x 10's | 087414 | PKR 4,521.01 | PKR 452.10/tablet | 🔒 Pharma Pro |
| Spdrox | Hydroxyurea | 500 mg | Capsule | 100's | 110497 | PKR 3,138.03 | PKR 31.38/capsule | 🔒 Pharma Pro |
| Tapentis IR Tablet 100mgRegistry verified | Tapentadol Hydrochloride Eq. to Tapentadol | — | — | — | 134916Official source ↗ | No indexed price | — | — |
| Tapentis IR Tablet 50mgRegistry verified | Tapentadol Hydrochloride Eq. To Tapentadol | — | — | — | 134918Official source ↗ | No indexed price | — | — |
| Tapentis IR Tablet 75mgRegistry verified | Tapentadol Hydrochloride Eq. to Tapentadol | — | — | — | 134917Official source ↗ | No indexed price | — | — |
| Tazcil Injection 2.25g (IV)Registry verified | Piperacillin as Sodium, Tazobactam as Sodium | — | — | — | 133126Official source ↗ | No indexed price | — | — |
| Thami | Thalidomide | 50 mg | Capsule | 1x10's | 135299 | PKR 525.00 | PKR 52.50/capsule | 🔒 Pharma Pro |
| Tixvita | Cholecalciferol | 5 mg | Injection | 5's | 114293 | PKR 964.48 | PKR 192.90/vial/unit | 🔒 Pharma Pro |
| Tixvita | Cholecalciferol | 5 mg | Injection | 1's | 114293 | PKR 192.90 | PKR 192.90/vial/unit | 🔒 Pharma Pro |
| Trezolid Tablet 200mgRegistry verified | Tedizolid Phosphate | — | — | — | 137225Official source ↗ | No indexed price | — | — |
| Tseroz-1mg | Tacrolimus | 1 mg | Capsule | 3 x 10's | 097168 | PKR 3,213.76 | PKR 107.13/capsule | 🔒 Pharma Pro |
| Tseroz-5mg | Tacrolimus | 5 mg | Capsule | 3 x 10's | 097169 | PKR 16,068.80 | PKR 535.63/capsule | 🔒 Pharma Pro |
| Udanib ER Tablet 15mgRegistry verified | Upadacitinib Hemihydrate Eq. to Upadacitinib | — | — | — | 134835Official source ↗ | No indexed price | — | — |
| Uniron | Recombinant human interferon alfa-2b | 3 MIU | Injection | 1's | 059242 | PKR 1,153.58 | PKR 1,153.58/vial/unit | No comparator |
| Unomox-400 | Moxifloxacin | 400 mg | Tablet | 1 x 5's | 056083 | PKR 947.39 | PKR 189.48/tablet | 🔒 Pharma Pro |
| Vagifest | Clotrimazole | 500 mg | Vaginal tablet | 1 x 1's | 042521 | PKR 127.65 | PKR 127.65/tablet | 🔒 Pharma Pro |
| Visral-50 | Miltefosine | 50 mg | Capsule | 56's | 090710 | PKR 31,061.04 | PKR 554.66/capsule | 🔒 Pharma Pro |
| Voricon | Voriconazole | 40 mg/5 mL | Dry suspension | 75ml | 084200 | PKR 3,223.62 | PKR 42.98/mL | No comparator |
| Voricon-200 | Voriconazole | 200 mg | Tablet | 1 x 10's | 075507 | PKR 2,312.94 | PKR 231.29/tablet | 🔒 Pharma Pro |
| Vudin | Lamivudine | 100 mg | Tablet | 2 x 7's | 079364 | PKR 797.80 | PKR 56.99/tablet | 🔒 Pharma Pro |
| Xempra | Omeprazole | 20 mg | Capsule | 1 x 10's | 046195 | PKR 205.43 | PKR 20.54/capsule | 🔒 Pharma Pro |
| Xempra | Omeprazole | 8.5 % | Capsule | 1 x 10's | 046195 | PKR 205.43 | PKR 20.54/capsule | No comparator |
| Xempra 40mg injectionRegistry verified | Omeprazole as sodium | — | — | — | 125532Official source ↗ | No indexed price | — | — |
| Xempra-40 | Omeprazole | 40 mg | Capsule | 1 x 10's | 060029 | PKR 357.02 | PKR 35.70/capsule | 🔒 Pharma Pro |
| Xempra-40 | Omeprazole | 8.5 % | Capsule | 1 x 10's | 060029 | PKR 357.02 | PKR 35.70/capsule | No comparator |
| Xerine-250 | Cycloserine | 250 mg | Capsule | 1 x 10's | 084201 | PKR 1,440.03 | PKR 144.00/capsule | 🔒 Pharma Pro |
| Xutin | Fluoxetine | 20 mg | Capsule | 1 x 10's | 059382 | PKR 129.64 | PKR 12.96/capsule | 🔒 Pharma Pro |
| Zevoxid | Linezolid | 600 mg | Tablet | 2 x 6's | 076809 | PKR 5,097.96 | PKR 424.83/tablet | 🔒 Pharma Pro |
| Zevoxid | Linezolid | 100 mg/5 mL | Suspension | 60ml | 078449 | PKR 698.08 | PKR 11.63/mL | 🔒 Pharma Pro |
| Zim | Azithromycin | 250 mg | Tablet | 1 x 10's | 042975 | PKR 508.60 | PKR 50.86/tablet | 🔒 Pharma Pro |
| ZimSource observed | Azithromycin | 200 mg | Held for normalizationSource reported: Tablet · structural field conflict | 15ml | 075531Official source ↗ | No indexed price | — | — |
| Zim 200 Dry Susp Azithromycin (as dihydrate)…………...200mgSource observed | — | — | — | 15ml | 075531Official source ↗ | No indexed price | — | — |
| Zincor | Zinc | 10 mg | Tablet | 2 x 10's | 064007 | PKR 123.59 | PKR 6.18/tablet | 🔒 Pharma Pro |
| Zincor-D | Zinc | 20 mg | Tablet | 1 x 30's | 080982 | PKR 297.06 | PKR 9.90/tablet | 🔒 Pharma Pro |
| Zincor-D | Zinc (elemental) | 20 mg | Tablet | 1 x 30's | 080982 | PKR 297.06 | PKR 9.90/tablet | No comparator |
| Zydex-100 | Clozapine | 100 mg | Tablet | 5 x 10's | 053559 | PKR 3,490.39 | PKR 69.81/tablet | 🔒 Pharma Pro |
| Zydex-25 | Clozapine | 25 mg | Tablet | 5 x 10's | 053558 | PKR 1,595.61 | PKR 31.91/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.